Open AccessMIB ‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy
Author(s) -
Yamamoto Eri,
Tomita Naoto,
Sakata Seiji,
Tsuyama Naoko,
Takeuchi Kengo,
Nakajima Yuki,
Miyashita Kazuho,
Tachibana Takayoshi,
Takasaki Hirotaka,
Tanaka Masatsugu,
Hashimoto Chizuko,
Koharazawa Hideyuki,
Fujimaki Katsumichi,
Taguchi Jun,
Harano Hiroshi,
Motomura Shigeki,
Ishigatsubo Yoshiaki
Publication year - 2013
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12288
Subject(s) - rituximab , follicular lymphoma , medicine , international prognostic index , lymphoma , vincristine , chop , non hodgkin's lymphoma , gastroenterology , proliferation index , grading (engineering) , oncology , pathology , chemotherapy , cyclophosphamide , immunohistochemistry , biology , ecology
The MIB ‐1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB ‐1 labeling index at the time of diagnosis, in 98 patients with follicular lymphoma ( FL ) grade 1–3b who were treated uniformly with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R‐ CHOP ) therapy. The 5‐year progression‐free survival ( PFS ) for an MIB ‐1 labeling index of ≥10% ( n = 60) and <10% ( n = 38) was 35% and 61%, respectively ( P = 0.015). The 5‐year overall survival ( OS ) for an MIB ‐1 labeling index of ≥10% and <10% was 77% and 92%, respectively ( P = 0.025). Pathological grading was not correlated with PFS or OS . In multivariate analysis, an MIB ‐1 labeling index of ≥10% was independently associated with poor PFS and OS. In conclusion, an MIB ‐1 labeling index of 10% is a useful cut‐off level for predicting the prognosis of patients with FL.